ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed Vice President of the ABPI to support UK life sciences ...

TOKYO -- Japanese pharmaceutical companies including Daiichi Sankyo and Fujifilm Holdings are increasing efforts to develop biopharmaceutical talent, aiming for 50% to 100% growth in such experts as ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

The global pediatric anticoagulant formulations market is valued at approximately $1.35 billion in 2024 and is projected to g ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.